| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Contents
|
|
|
|
40 |
3 |
p. v-vii
|
artikel
|
| 2 |
Contributors
|
|
|
|
40 |
3 |
p. iii-iv
|
artikel
|
| 3 |
Copyright
|
|
|
|
40 |
3 |
p. ii
|
artikel
|
| 4 |
Cutaneous Pharmacokinetic Approaches to Compare Bioavailability and/or Bioequivalence for Topical Drug Products
|
Raney, Sam G.
|
|
|
40 |
3 |
p. 319-332
|
artikel
|
| 5 |
Dermatology Drugs for Children—U.S. Food and Drug Administration Perspective
|
Epps, Roselyn E.
|
|
|
40 |
3 |
p. 289-296
|
artikel
|
| 6 |
Food and Drug Administration’s Role in Dermatology
|
Luke, Markham C.
|
|
|
40 |
3 |
p. i
|
artikel
|
| 7 |
Food and Drug Administration’s Role in Dermatology
|
Brod, Bruce A.
|
|
|
40 |
3 |
p. ix
|
artikel
|
| 8 |
Forthcoming Issues
|
|
|
|
40 |
3 |
p. viii
|
artikel
|
| 9 |
How Does the Food and Drug Administration Approve Topical Generic Drugs Applied to the Skin?
|
Ghosh, Priyanka
|
|
|
40 |
3 |
p. 279-287
|
artikel
|
| 10 |
Measuring What Matters to Patients in Dermatology Drug Development
|
Daniels, Selena R.
|
|
|
40 |
3 |
p. 333-337
|
artikel
|
| 11 |
Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions
|
Reyes, Melissa
|
|
|
40 |
3 |
p. 265-277
|
artikel
|
| 12 |
Regulation of Cosmetics in the United States
|
Katz, Linda M.
|
|
|
40 |
3 |
p. 307-318
|
artikel
|
| 13 |
Regulation of Medical Devices for Dermatology
|
Halachmi, Shlomit
|
|
|
40 |
3 |
p. 297-305
|
artikel
|
| 14 |
The Food and Drug Administration’s Role in Dermatologic Drug Development
|
Lewis, Felisa S.
|
|
|
40 |
3 |
p. 249-263
|
artikel
|
| 15 |
The History of Dermatology and Dermatologists at the US Food and Drug Administration
|
Burrows, Vanessa L.
|
|
|
40 |
3 |
p. 237-248
|
artikel
|
| 16 |
The US Food and Drug Administration’s Intersection with Dermatology
|
Luke, Markham C.
|
|
|
40 |
3 |
p. xi-xii
|
artikel
|
Tijdschrift beschrijving